Docor International Management
VC Fund
Tel Aviv, Israel
Docor International Management is a VC fund in Tel Aviv focused on Health Care and Biotechnology. Docor International B.V. is a fully-owned subsidiary of Crecor B.V. Both Docor and Crecor were formed as wholly-owned subsidiaries of the Van Leer Group Foundation to promote and participate in commercial activities in Israel.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Docor International Management invests in
Stages Docor International Management invests in
Countries Docor International Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series C
- $13M–$22M
Investment Focus
Industry
- Health Care 8 (57%)
- Biotechnology 7 (50%)
- 3D Technology 3 (21%)
- Medical Device 3 (21%)
- Pharmaceutical 3 (21%)
Stage
- Funding Round 5 (36%)
- Series C 2 (14%)
- Series A 1 (7%)
- Series B 1 (7%)
- Series D 1 (7%)
Country
- Israel 10 (71%)
- United States 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adi Goldin
Director of business development
|
Director of business development | Total investments: 2 | Find email | |
Anat Klein
Member
|
Member | Total investments: 0 | Find email | |
Andre Betting
Foundation Executive Director
|
Foundation Executive Director | Total investments: 0 | Find email | |
Gideon Frank
Member
|
Member | Total investments: 0 | Find email | |
Rien Van Gendt
Member
|
Member | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Raziel Health
|
Raziel Health’s mission is to bring world-class, disruptively less expensive healthcare to everyone, in the comfort of their home. Its unique, integrated system combines easy-to-use technologies that support positive patient experience, enable timely clinical intervention, and meet individual patient goals while using data analytics to supportwellness and disease management. | $22M / Series C / Dec 18, 2019 | |
Ocon Healthcare
|
OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility. | $15M / Jan 29, 2016 | |
Check-Cap
|
Check-Cap is a young and dynamic medical device company with breakthrough solution for Colorectal Cancer Screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is expected to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy. | $12M / Debt Financing / Oct 19, 2014 | |
SP Nano
|
SP Nano is a nanotechnology company commercializing the use of nano-particles in the rapidly growing $106 billion composites market. The most widely-used type of composite consists of layers of fabric (carbon-fiber, glass-fiber, aramid) held together by a resin matrix. The matrix is the materials' weakest link - much weaker than the layersof fibers it binds. When composite structures and components commonly used in the aerospace, defense, automotive, marine and sporting goods industries fail, it's often because of this large discrepancy in strength between the fibers and the resin. | $2M / Series B / Jun 20, 2014 | |
EarlySense
|
EarlySense develops signal-processing technology. The company's lead product, EverOn, a contact-free early detection patient supervision system that measures, records, displays, and alerts heart and respiration rates, as well as bed entries and exits, patient motion, and quality of sleep from under the mattress. EarlySense Ltd. was founded in2004 and is based in Ramat Gan, Israel with a research and development facility in Israel; and marketing offices in Boston, Massachusetts. | $15M / Series E / Nov 12, 2012 | |
|
SP Nano
|
SP Nano is a nanotechnology company commercializing the use of nano-particles in the rapidly growing $106 billion composites market. The most widely-used type of composite consists of layers of fabric (carbon-fiber, glass-fiber, aramid) held together by a resin matrix. The matrix is the materials' weakest link - much weaker than the layersof fibers it binds. When composite structures and components commonly used in the aerospace, defense, automotive, marine and sporting goods industries fail, it's often because of this large discrepancy in strength between the fibers and the resin. | $3.3M / Series A / Jun 01, 2012 | |
MacroCure
|
MacroCure is a biotechnology company focused on the development and commercialization of advanced cell therapy products. The company's first focus of interest is in the arena of wound care. The technology employs activated white blood cells obtained from young adults healthy donor blood. The activated cells provide the natural environment forwound healing, and ensure that necessary cell activities and factor secretions are maintained as required for wound healing. This novel concept is the first of its kind in the field of wound therapy. | $13M / Apr 01, 2011 | |
|
EarlySense
|
EarlySense develops signal-processing technology. The company's lead product, EverOn, a contact-free early detection patient supervision system that measures, records, displays, and alerts heart and respiration rates, as well as bed entries and exits, patient motion, and quality of sleep from under the mattress. EarlySense Ltd. was founded in2004 and is based in Ramat Gan, Israel with a research and development facility in Israel; and marketing offices in Boston, Massachusetts. | $13M / Series C / Jul 23, 2010 | |
Aposense
|
Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel. | $7.3M / Aug 20, 2008 | |
Collplant
|
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk isideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel. | $8.3M / Apr 01, 2008 | |
| See all 14 investments → | |||
Co-Investors
Pontifax
8 deals together
Bridge Investment Fund
2 deals together
iNetworks 360
2 deals together
L&S Venture Capital
2 deals together
Pitango VC
2 deals together
The Challenge Fund
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Docor International Management invest in?
Docor International Management invests primarily in Health Care, Biotechnology and 3D Technology startups, most often at Funding Round and Series C stage. Most of the 14 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Docor International Management's check size?
Docor International Management typically joins rounds of $13M–$22M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Docor International Management participates in.
How do I contact Docor International Management?
Public channels for Docor International Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Docor International Management?
The team at Docor International Management includes Adi Goldin (Director of business development), Anat Klein (Member) and Andre Betting (Foundation Executive Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
